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Abstract
Background: The studies on the effectiveness of Chinese herbal medicines (CHM) in treating liver fibrosis (LF) were
not consistent. This study aims to systematically review the effectiveness of CHM on treating LF patients.
Methods: Databases including MEDLINE, AMED, EMBASE, The Cochrane Central Register of Controlled Trials, China
National Knowledge Infrastructure, TCMOnline, Chinese Biomedical Literature Database, and Chinese Medical
Current Contents were searched up to March 2011. Randomized controlled trials (RCTs) involving LF patients
receiving CHM, Western medicine, combined CHM and Western medicine compared with placebo, Western
medicine or no intervention were included. LF markers including serum hyaluronic acid (HA), laminin (LN),
procollagen type III (PC-III), type IV collagen (IV-C), matrix metalloproteinase (MMP), and tissue inhibitors of
metalloproteinase (TIMP) were measured as primary outcomes. Liver biochemistry, including alanine
aminotransferase (ALT) and aspartarte aminotransferase (AST), and improvement of related clinical symptoms were
measured as secondary outcomes. Risk of bias of allocation sequence, allocation concealment, blinding, incomplete
outcome data, selective outcome reporting, and other biases were assessed.
Results: Twenty-three RCTs with 2123 participants were analyzed in subgroups of types of comparison and study
quality. Fifteen studies were graded as good quality. CHM alone and combined with Western medicine showed
significant improvements in HA, LN, PC-III and IV-C compared with Western medicine alone. However, there were
no significant differences observed between CHM and placebo treatments.
Conclusion: The current inconclusive results in determining the effectiveness of CHM treatment on LF, due to the
poor methodological quality and high heterogeneity of the studies, suggests that large RCTs using standardized
Chinese medicine syndrome diagnosis and CHM formulae with longer follow-up are required for further evaluation.
Introduction
Liver fibrosis (LF), as a result of wound-healing response
to recurrent liver injury, is thought to be an early rever-
sible stage of liver cirrhosis [1]. It is characterized by the
formation of fibrotic scar tissue with abnormal accumu-
lation of fibroblasts and myofibroblasts, and excessive
synthesis and deposition of extracellular matrix (ECM)
proteins. The development of anti-fibrotic therapy is
important for patients with chronic liver diseases, espe-
cially for chronic hepatitis B (HBV) and C virus (HCV)
infections [2], which are the most prevalent blood-borne
viral infection and the major causes of LF worldwide,
especially in mainland China [3-5]. Few LF treatments
are effective and inexpensive without adverse side effect
[6-8].
Categories of current research into Chinese herbal
medicine (CHM) treatment of LF include (1) the preven-
tion of anti-fibrosis effects, (2) mechanisms, and (3) clini-
cal efficacy, safety and quality control [3]. Clinically,
several studies reported the efficacy of CHM on LF
[9-11]. A previous systematic review of 11 studies on LF
suggested that “Fuzheng Huayu Capsule“ had beneficial
effects on LF [12]. However, the review included only
one CHM compound, and the results might not be repre-
sentative of all CHM. Moreover, with advanced progress
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include recent studies.
This article aims to systematically review the pub-
lished randomized controlled trials (RCTs) for evaluat-
ing the effectiveness of CHM on LF treatment.
Methods
This study was conducted according to the Cochrane
practice [13,14], including pre-specified objectives,
search strategy, inclusion criteria, quality assessment,
data collection and meta-analysis.
Search strategy
Published RCTs on CHM treating LF patients were
searched via the following electronic databases from
their inception to March 2011: MEDLINE since 1948,
AMED since 1985, EMBASE since 1974, and The
Cochrane Central Register of Controlled Trials since
1996. In addition, four Chinese electronic databases
including China National Knowledge Infrastructure
(CNKI), TCMOnline, Chinese Biomedical Literature
Database (CBM), and Chinese Medical Current Con-
tents (CCMC) were searched since January 2000. The
bibliographies of studies identified in the systematic
search were checked for potentially relevant publica-
tions. Unpublished data were not included.
The keywords for database search were (’liver fibrosis’
OR ‘hepatic fibrosis’ OR ‘fibrotic liver’ OR ‘antifibrotic’)
AND (’Chinese medicine’ OR ‘traditional medicine’ OR
‘herbal medicine’ OR ‘complementary medicine’ OR ‘com-
plementary therapy’ OR ‘alternative medicine’ OR ‘Fuz-
heng huayu’ OR ‘compound 861’ OR ‘Anluohuaxian pill’
OR ‘Rhubarb zhechong wan’ OR ‘Sho saiko to’ OR ‘Fufang
biejiaruangan tablet’ OR ‘Biejia ruanjian’ OR ‘Biejiajian
pill’ OR ‘Qianggan capsule’ OR ‘Qianggan pill’ OR ‘Han-
Dan-Bi-Tuo’ OR ‘Matrine capsule’ OR ‘Oxymatrine cap-
sule’ ) AND ‘randomized controlled trial’ [15]. No restric-
tions on publication type and language of publication were
imposed.
Study selection
Types of studies
This review included only RCTs on the effectiveness of
CHM. The studies with quasi-randomized and non-ran-
domized study design were excluded.
Participants
The studies recruited patients suffering from chronic
hepatitis diseases, fatty liver or schistosomiasis japonica,
and having histologically significant LF were included.
The studies involved patients having co-infection of two
or more types of hepatitis or fatty liver with other
chronic liver diseases, or having decompensated liver
diseases were excluded.
Interventions
The studies comparing CHM (such as pills, tablets, cap-
sules, decoctions, and injections) with placebo, Western
medicine, or no intervention were included. CHM inter-
vention could be a sole anti-fibrotic therapy or an adjunct
treatment. The studies assessing combined effects of CHM
with other intervention (e.g. CHM plus acupuncture, injec-
tion of CHM into acupoint, and acupoint application) were
excluded. The studies used non-conventional herbal medi-
cines or complementary medicines as control groups were
also excluded. Co-intervention, including those supple-
m e n t ss u c ha sv i t a m i n s ,w a sa l l o w e di fb o t ha r m so ft h e
randomized allocation received the same co-intervention.
Outcome measures
Primary outcome measures were mean differences (MD)
of LF biomarkers, which indicate ECM metabolism,
including serum hyaluronic acid (HA), laminin (LN), pro-
collagen type III (PC-III), type IV collagen (IV-C), matrix
metalloproteinase (MMP), and tissue inhibitors of metal-
loproteinase (TIMP) [16]. Secondary outcomes included
liver biochemistry which including alanine aminotrans-
ferase (ALT) and aspartarte aminotransferase (AST), and
the improvement of related clinical symptoms was
defined as the alleviation of subjective symptoms after
the interventions. Both non-serious and serious adverse
events were evaluated. A serious adverse event included
event of death, life-threatening incidents, or inpatient or
prolonged of hospitalization which resulted in a persis-
tent or significant disability [17].
Data extraction and assessment of methodological
quality
Two authors (FC and NW) independently assessed stu-
dies for eligibility, extracted data in duplicate using a
structured data extraction form, and cross-checked for
transcription errors. The data extraction form comprised
the items of primary author, study citation, study design,
participants, interventions, outcome measures, and
adverse events according to pre-specific selection criteria.
In case duplicate publications were found, only the most
informative and updated version was included. The qual-
ity of included studies was evaluated independently by
the two authors (FC and NW) using a tool for evaluating
‘risk of bias’ which tool was adapted from the Cochrane
Handbook for Systematic Review of Interventions [13]
with slight modifications for transforming the bias codes
of “yes”, “unclear” and “no” into 2, 1 and 0, respectively,
for presenting clearer results. The following six questions
were asked:
(1) Was the allocation sequence adequately generated?
(2) Was allocation adequately concealed?
(3) Was knowledge of the allocated interventions ade-
quately prevented during the study?
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addressed?
(5) Are reports of the study free of suggestion of selec-
tive outcome reporting?
(6) Was the study free of other problems that could
put it at a risk of bias?
Every item would be given 2 points for answering ‘yes’,
1 for answering ‘unclear’ and 0 for answering ‘no’.P r e -
vention of knowledge of the allocated interventions, i.e.
blinding (patient, personnel, and outcome assessor
blinding), was assessed separately. There were eight
items in total as three items from blinding (including
blinding of patients, personnel, and outcome assessor),
and five from the rest five questions. The scale ranged
from 0 to 16 points with 0 to 7 regarded as poor quality,
and 8 or above as good quality. Any disagreement was
resolved by consensus. If necessary, the third author
(YF) was consulted for resolution.
Data synthesis of outcome measures
Review Manager, Version 5.1 for Windows (The Nordic
Cochrane Centre, Copenhagen, Denmark) and STATA
10.1 (StataCorp, College Station, TX, USA) were used for
data analysis. Meta-analysis was carried out on the inten-
tion-to-treat (ITT) basis regardless whether the subjects
were lost to follow-up. Subgroup analysis was conducted
among different comparisons (including CHM versus
Western medicine, CHM versus placebo, and combined
treatment versus Western medicine) and study quality
(all studies versus the studies with good quality). Inverse-
variance random effects model was used MD and 95%
confidence intervals (CI) were calculated. Heterogeneity
was assessed by examining the forest plots and I
2 statis-
tics, where I
2 values of 25%, 50%, and 75% were regarded
as low, moderate, and high heterogeneity, respectively
[18]. Sensitivity analysis for primary outcomes was per-
formed to assess the impact of excluding outlier studies
when there was high heterogeneity (I
2 > 75%) between
studies. In a three-arm study that had two control groups
of conventional medicine and no intervention, the treat-
ment group was split into two groups to create two com-
parisons in the meta-analysis. Funnel plot and Egger’s
regression asymmetry test were applied to detect for the
potential publication bias [19]. P value less than 0.05
were considered statistically significant.
Results
Study characteristics
Figure 1 shows the process of the study selection.
Twenty-three RCTs with a total of 2123 participants
met the eligibility criteria were included in this review
(Table 1). Sample sizes ranged from 44 to 164. Among
these included studies, a study recruited schistosomiasis
japonica patients only [20], the remaining recruited
patients with chronic HBV infection. All of the identi-
fied studies were conducted in China and published in
Chinese language, and only one study was published in
English language [21]. Three studies used three-arm
study design (2 intervention groups compared with 1
control group, or 1 intervention group compared with 2
control groups) [21-23] and others used two-arm study
design (1 intervention group versus 1 control group)
[20,24-42]. No study reported mortality, liver cirrhosis
or cancer, quality of life or cost as outcomes. The infor-
mation about the study design, participants, interven-
tion, outcome assessment, and quality was presented in
Additional file 1.
Treatment groups
The types of intervention were classified as CHM (N =
8) and combined treatment (CHM plus Western medi-
cine) (N = 15) including Interferon (IFN), Entecavir,
Adefovir Dipivoxil, and Lamivudine (LVD). CHM was
prepared as decoctions (N = 7), tablets (N = 8), granules
(N = 2), capsules (N = 2), pills (N = 3), and oral liquid
(N = 1). Only standardized (87%, 20/23) and semi-stan-
dardized (13%, 3/23) CHM prescriptions were used in
these studies. The standardized prescriptions indicate fix
formulas for all participants and the semi-standardized
prescriptions were defined as individually customized
formulas according to Chinese medicine.
Control groups
Comparison groups included Western medicines
(including IFN, Entecavir, Adefovir Dipivoxil, and LVD),
placebo, and no intervention. Three studies used place-
bos, with one using physiological saline and food color-
ing [30], and two using similar shape capsules [20,41].
Duration of follow-up
The range of intervention duration in the studies ranged
from 60 days to two years with mostly were six months
(N = 7) and one year (N = 7). The duration of follow-
up was only reported in three studies with a range from
three to six months [27,30,34].
Methodological quality
Fifteen studies were graded as good quality and others
as poor quality (as shown in Additional file 1). Out of
23 included studies, only two studies reported adequate
generation of allocation sequence using random number
tables or drawing of lots for assigning groups [29,41].
None of the studies described the method of allocation
concealment. Only one study reported using blinding
design (single blind without description of the blinding
method) [21] and three studies used placebos [20,30,41].
Six studies did not provide the information on missing
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Medline (n = 121) 
AMED (n = 1) 
Cochrane (n = 3) 
EMBASE (n = 93) 
CNKI (n = 720) 
CBM (n = 428) 
CMCC (n = 247) 
TCMOline (n = 153) 
ʳ
ʳ
ʳ
ʳ
ʳ
Publications excluded after screening the title and 
abstract (n = 1455): 
Review articles (n = 45); 
Non clinical trials (n = 301); 
Inappropriate population, intervention and outcome measure 
(n = 974); 
Duplicates (n = 135) 
Full-text for detailed evaluation   
(n = 311)
Publications excluded (n = 288): 
Non RCTs (n = 41); 
Intervention not meeting inclusion criteria (n = 7); 
Patient not diagnosed LF (n = 55); 
CHM used in the control group (n = 123); 
Control group not Western medicine, placebo or no 
intervention (n = 40); 
Other reasons (n = 22) 
Publications selected for appraisal (n = 23): 
Chinese studies (n = 22); 
English studies (n = 1)
Trials included in meta-analysis (n = 21): 
CHM versus Western medicine (n = 6); 
CHM combined with Western medicine versus Western medicine (n = 14); 
CHM versus placebo (n = 3) 
Figure 1 Flow diagram of study selection process.
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Study ID Sample
size
Intervention Group Control
Group
Duration Primary Outcomes Secondary Outcomes
Chen 2005 [24] 49 ‘Fufang Biejia Ruangan
Tablets’ + IFN-g (n = 28)
IFN-g (n = 21) 6 months HA, LN, PC-III, IV-C &
Knodell score
ALT & AST
Chen 2006 [33] 116 Kang Xian Decoction + IFN-a
(n = 58)
IFN-a (n = 58) 6 months HA, LN & PC-III ALT & Improvement of
related clinical symptoms
Chen 2006_2 [20] 138 ’Qianggan Capsule’ +
conventional care (n = 68)
Placebo +
conventional
care (n = 70)
6 months HA, LN, PC-III & IV-C ALT, Improvement of
related clinical symptoms
Chen 2007 [22] 164 Group I: Bie Jia Jian Pills +
conventional care (n = 54)
IFN +
conventional
care (n = 52)
9 months HA, LN & PC-III
Group II: Group I + control
group (n = 58)
Chen 2010 [25] 96 ’Fufang Biejia Ruangan
Tablets’ + Entecavir (n = 46)
Entecavir
(n = 50)
1 year HA, LN, PC-III & IV-C ALT & AST.
Dai 2011 [26] 68 ’Fufang Biejia Ruangan
Tablets’ + Entecavir (n = 34)
Entecavir
(n = 34)
1 year HA, LN, PC-III & IV-C ALT, AST & Improvement
of related clinical
symptoms
Gao 2000 [34] 120 ’HB-Granule-3’ (n = 60) IFN-a (n = 60) 90 days HA, LN & IV-C ALT & Improvement of
related clinical symptoms
Huang 2007 [27] 99 ’Decoction of Radix Salviae
Milltorrhizae, Radix Astragali
and Rhubarb’ (n = 50)
IFN-a (n = 49) 3 months HA, LN, PC-III & IV-C ALT & AST
Huang 2009 [28] 83 ’Fufang Biejia Ruangan
Tablets’ + Adefovir dipivoxil
(n = 43)
Adefovir
dipivoxil
(n = 40)
1 year ALT & AST
Kuang 2005 [29] 53 Bie Jia Jian Decoction
(n = 27)
LVD (n = 26) 60 days HA, PC-III & IV-C ALT, AST & Improvement
of related clinical
symptoms
Li 2006 [30] 60 ’Xiexian Oral Liquid’ +
conventional care (n = 30)
Placebo +
conventional
care (n = 30)
4 months HA, LN & IV-C ALT, AST & Improvement
of related clinical
symptoms
Li 2011 [31] 88 ’Anluo Huaxian Pills’ +
Adefovir dipivoxil (n = 44)
Adefovir
dipivoxil
(n = 44)
9 months HA, LN, PC-III & IV-C ALT & AST
Lu 2010 [32] 82 ’Fufang Biejia Ruangan
Tablets’ + Adefovir dipivoxil
(n = 42)
Adefovir
dipivoxil
(n = 40)
1 year HA, LN, PC-III & IV-C ALT, AST & Improvement
of related clinical
symptoms
Shen 2003 [35] 68 ’Ganxian Prescirption’ + LVD
(n = 31)
LVD (n = 37) 1 year HA, LN & IV-C ALT & AST
Shen 2005 [21] 120 Group I: ‘Ganxian Recipe’
(n = 40)
LVD (n = 40) 2 years HA, LN & IV-C ALT & AST
Group II: ‘Ganxian Recipe’ +
LVD
(n = 40)
Sun 2010 [36] 55 ’Anluo Huaxian Pills’ +
Adefovir dipivoxil (n = 30)
Adefovir
dipivoxil
(n = 25)
48 weeks HA, LN, PC-III & IV-C ALT, AST & Improvement
of related clinical
symptoms.
Wang 2006 [23] 160 Group I: experienced clinical
decoction (n = 50)
LVD (n = 50) 6 months HA, LN, PC-III & IV-C
Group II: Group I + Control
Group (n = 60)
Wang 2010 [37] 98 ’Fufang Biejia Ruangan
Tablets’ + Adefovir dipivoxil
(n = 49)
Adefovir
dipivoxil
(n = 49)
1 year HA, LN, PC-III & IV-C ALT
Wei 2010 [38] 44 ’Fufang Biejia Ruangan
Tablets’ + Adefovir dipivoxil
(n = 22)
Adefovir
dipivoxil
(n = 22)
1 year HA, LN, PC-III & IV-C ALT & AST
Xie 2009 [39] 62 ’Huaxian Fugan Prescription’
+ conventional care (n = 32)
Conventional
care (n = 30)
6 months HA, LN, PC-III & IV-C ALT, AST & Improvement
of related clinical
symptoms
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their analysis.
Outcomes
Primary outcomes
Figures 2, 3, 4 show the forest plots of MD of LF mar-
kers (HA, LN, PC-III & IV-C) with 95% CI.
CHM group versus Western medicine group (6
studies):
CHM significantly reduced the levels of HA (pooled
MD-31.52; 95% CI-40.65, -22.38; P < 0.00001), LN
(pooled MD-43.62; -77.41, -9.82; P = 0.01), PC-III
(pooled MD-115.37; -203.65, -27.09; P = 0.01) and IV-C
(pooled MD-29.05; -53.4, -4.7; P = 0.02), with I
2 ranging
from 89% to 98%, as shown in Figure 2. Subgroup ana-
lyses among studies with different quality also found
substantial significant differences in favor of CHM in
the levels of HA (pooled MD -292.65; 95% CI-481.77,
-103.54; P = 0.002), LN (pooled MD-76.28; -136.23,
-16.32; P = 0.01), PC-III (pooled MD-115.37; -203.65,
-27.09; P=0.01) and IV-C (pooled MD -52.05; -93.95,
-10.15; P =0 . 0 1 ) ,w i t hI
2 ranging from 86% to 98%. The
significance differences were maintained for the levels of
HA (pooled MD - 21.46; 95% CI -30.80, - 12.13; P <
0.00001), LN (pooled MD -21.01; 95% CI -43.49, 1.47;
P = 0.07), and IV-C (pooled MD -15.65; 95% CI -34.57,
3.26; P = 0.1) when excluding the studies with outlier
results, with I
2 ranging from 83% to 96%. For PC-III
(pooled MD -221.02; 95% CI -271.89, -170.15; P <
0.00001), the heterogeneity was largely reduced after
removing two potential outlier studies [27,29] (overall
I
2 = 0%).
CHM group versus placebo group (3 studies):
CHM had no significant effects on the levels of HA
(pooled MD -77.82; 95% CI-156.67, 1.03; P = 0.05), LN
(pooled MD -74.59; -167.93, 18.75; P =0 . 1 2 ) ,P C - I I I
(pooled MD -17.09; -51.09, 16.91; P =0 . 3 2 )a n dI V - C
(pooled MD -43.71; -98.45, 11.03; P =0 . 1 2 )w h e nc o m -
pared with placebo, with I
2 ranging from 93% to 99%, as
shown in Figure 3. Subgroup analysis showed the same
estimates for quality and sensitivity analyses excluding
outliers found similar results for the levels of HA
(pooled MD -41.80; 95% CI-109.68, 26.08; P = 0.23), LN
(pooled MD -11.51; 95% CI -46.48, 23.46; P = 0.52), and
IV-C (pooled MD -19.69; 95% CI-49.15, 9.76; P = 0.19)
A large high heterogeneity was observed (I
2 ranging
from 87% to 92%) except in IV-C (I
2 = 49%).
Combined treatment group versus Western medicine
group (14 studies):
Combined treatment was found to significantly reduce
the levels of HA (pooled MD -46.59; 95% CI -51.23,
-41.944; P < 0.00001), LN (pooled MD -40.292; -57.13,
-23.45; P < 0.00001), PC-III (pooled MD -4.49; -6.68, -2.3;
P < 0.0001) and IV-C (pooled MD -38.81; -54.84, -22.78; P
< 00001) compared with Western medicine, Western
medicine, with I
2 ranging from 92% to 96%, as shown in
Figure 4. Subgroup analyses showed high significant differ-
ences for good quality studies in the levels of HA (pooled
MD -121.46; 95% CI-166.40, -76.51; P < 0.00001), LN
(pooled MD -58.53; -88.38, -28.68; P = 0.0001), PC-III
(pooled MD) - 13.14; -18.81, -7.48; P < 0.00001), and IV-C
(pooled MD -44.45; -68.17, -20.73; P = 0.0002), with I
2
ranging from 93% to 97%. Sensitivity analyses excluding
outliers found similar estimated and heterogeneity in the
levels of HA (pooled MD -41.94; 95% CI-46.65, -37.23; P <
0.00001), LN (pooled MD -24.22; -33.77, -14.67; P <
0.00001), PC-III (pooled MD -2.57; -4.20, -0.94; P =0 . 0 0 2 )
and IV-C (pooled MD -30.53; -44.35, -16.70; P < 0.0001),
with I
2 ranging from 80% to 94%.
Secondary outcomes
Comparing with Western medicine, combined treatment
was statistically significant in reducing ALT level (pooled
MD -11.35; 95% CI -18.75, -3.95; I
2 = 85%; P = 0.003). No
significant difference was found in AST level (pooled MD
-1.13; 95% CI -6.56, 4.3; I
2 =5 2 % ;P = 0.68). However,
when comparing CHM with Western medicine and pla-
cebo, no significant difference was found for the levels of
ALT (For CHM versus Western medicine: pooled MD
-14.59; 95% CI -37.190, 8; I
2 = 95%; P = 0.21. For CHM
versus placebo: pooled MD -18.64; -52.89, 15.61; I
2 =7 3 % ;
P =0 . 2 9 )a n dA S T( F o rC H Mversus Western medicine:
pooled MD 9.7; -3.37, 22.76; I
2 = 88%; P = 0.15. For CHM
versus placebo: pooled MD -17.94; -37.57, 1.69; I
2 = 37%;
P = 0.07).
Eleven studies [20,26,29,30,32-34,36,39,41,42] reported
symptom improvement with eight studies [20,29,30,32,
33,36,39,42] reported statistically significant difference (P <
0.05) in the outcomes comparing CHM with Western
Table 1 Characteristics of the included studies (Continued)
Yang 2009 [40] 120 ’Fufang Biejia Ruangan
Tablets’ + LVD +
conventional care (n = 60)
LVD +
conventional
care (n = 60)
6 months HA, LN, PC-III & IV-C ALT & AST
Yin 2004 [41] 102 ’Herbal Compound 861’
(n = 52)
Placebo (n =
50)
24 weeks HA, LN, PC-III, IV-C, MMPI,
MMP2, MMP9, TIMPI &
TIMP2
ALT, AST & Improvement
of related clinical
symptoms
Zhang 2000 [42] 78 ’Kanggan Xianfang’ +
conventional care (n = 39)
Conventional
care (n = 39)
6 months HA, PC-III & TGF-b1 ALT & Improvement of
related clinical symptoms
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Figure 4 Forest plot of studies comparing combined medicine and western medicine, examining the effect on liver fibrosis markers
(including HA, LN, PC-III and IV-C). (A). HA. (B) LN. (C) PC-III. (D) IV-C.
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Page 9 of 12medicine, placebo, and no intervention; and comparing
combined treatment with Western medicine. One out of
the eleven studies comparing CHM with placebo reported
a non-significant improvement [41].
Adverse events
Although adverse events were reported in nine studies,
none was serious. Among these, three reported no
adverse event in both groups [31,32,35] while one
reported no adverse event for CHM [30]. Five reported
gastrointestinal discomfort and drug-allergic symptoms
for CHM, placebo, IFN and LVD [20,21,27,30,41]. One
reported two cases with dizziness using the combined
treatment [21]. Other adverse symptoms of flu-like
symptoms or mild leucopenia and thrombocytopenia
were related to the use of IFN or LVD [21,22,27]. No
study described the method of data collection for
adverse events.
Evaluation of publication bias
Publication bias was found for HA (P = 0.003), PC-III (P =
0.001) and LN (P = 0.047) although non-significant for IV-
C( P = 0.814) according to Egger’s test. However, visual
inspection of the funnel plots (please see funnel plots in
Additional file 2) found no obvious basis.
Discussion
Overall findings
The levels of LF markers were significantly reduced in
patients receiving CHM or combined treatment com-
pared with Western medicine. The levels were signifi-
cantly decreased in CHM group compared with no
intervention although the effect was not significantly dif-
ferent when in comparison with Western medicine or
placebo. Moreover, CHM was found to be effective in
symptom improvements. It should be noted that CHM
was not consistently better than placebo.
Methodological quality of studies
Eight studies [21,25,28,31,33,34,36,37] were assessed to
be poor quality according to modified Cochrane ‘risk of
bias’ scale. Only two studies reported the method of
randomization [34,41]. The method of allocation con-
cealment was not reported by all studies, which should
be alert to the possibility of selection bias and overesti-
mation of intervention effects [43]. Blinding was not
reported or inappropriately reported by most of the stu-
dies. Although most studies used objective outcome
measures, it did not rule out the possibility of perfor-
mance bias and detection bias [44].
Potential biases
Strict eligibility criteria were used to reduce heterogeneity.
The included studies, however, had various participants’
characteristics and different CHM or combined treatment
against different control interventions. Small sample sizes,
methodological differences between studies and variations
in study objectives might contribute to heterogeneity. To
investigate the high levels of heterogeneity in this meta-
analysis we performed subgroup analysis and sensitivity
analysis. These analyses did not find inconsistency.
Some high quality studies might be missed due to the
strict eligibility criteria such as a multicentre, double
blinded RCT comparing “Fuzhenghuayu capsule“ with
“Heluoshugan capsule“ [45]. Other reviews including
CHM as control may be needed in the future. As most
studies were of small scale and poor methodological
quality, large RCTs of high quality would be required for
determining the effectiveness of CHM on LF treatment.
In order to minimize bias in the review, we did not
restrict the publication type and language, and searched
many commonly accessed databases. However, all iden-
tified studies were conducted in China, and studies
more likely reported positive results, which may be
influenced by publication and location bias [46-48]. Our
analysis of publication bias using Egger’st e s td i ds h o w
publication bias in the outcomes of HA, LN, and PC-III,
although the funnel plots were symmetric in distribution
(Additional file 2).
Limitations and further research
Most of the current studies only focused on the effec-
tiveness of intervention [49] but neglected monitoring
the harmful effect from CHM. Further studies should
assess both the safety and effectiveness. Well-designed,
multi-centre and large sample size RCTs in compliance
with the CONSORT guideline [50] should be implemen-
ted. Studies with CHM should be registered before their
conduct.
Conclusion
The current inconclusive studies are of poor methodolo-
gical quality and high heterogeneity do not adequately
support the effectiveness of CHM treatment on LF.
Large RCTs using standardized Chinese medicine syn-
drome diagnosis and CHM formulae with longer follow-
up are required for further evaluation.
Additional material
Additional file 1: Details of characteristics and methodological
quality of the included studies.
Additional file 2: Funnel plots (with pseudo 95% CI) for the primary
outcomes (including HA, LN, PC-III and IV-C) of the included studies
in the meta-analysis. (A) HA. (B) LN. (C) PC-III. (D) IV-C.
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